PD L1 News and Research

RSS

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

AI turns routine pathology slides into powerful maps of the tumor immune landscape

A large study shows that routine H&E pathology slides contain rich spatial proteomic signals that can be decoded by AI to model the tumor immune microenvironment at population scale. By generating virtual multiplex immunofluorescence images, GigaTIME enables pan-cancer discovery of immune patterns linked to invasion stage, survival, and genomic alterations.

10 Dec 2025

Enhancing the cancer-immunity cycle through innovative vaccines

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies.

14 Nov 2025

Alzheimer’s breakthrough reveals how tweaking one gene shields brain connections

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid, blocks tau spread, and preserves synapses in Alzheimer’s disease. Microglial CD28 signaling helps restrain inflammation, revealing a regulatory switch that may inform future immunotherapies targeting microglia rather than neurons.

6 Nov 2025

New combination treatment overcomes resistance in ER positive breast cancer

In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.

6 Nov 2025

Lactate and lactylation drive metabolic, epigenetic reprogramming in gynecological cancers

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression.

31 Oct 2025

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and temozolomide chemotherapy.

30 Oct 2025

Scripps Research professor wins $3.2 million grant to unravel the mysteries of type 1 diabetes

Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to help answer how type 1 diabetes manifests and develop potential therapeutics to reverse or prevent the disease.

29 Oct 2025

Targeting myeloid cells to enhance cancer immunotherapy

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer.

29 Oct 2025

How COVID mRNA vaccines may make cancer treatments more effective

Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were linked to significantly longer survival in lung and melanoma cancer patients. The vaccines trigger a powerful type-I interferon response that primes tumors to become more responsive to immunotherapy.

23 Oct 2025

Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.

18 Oct 2025

Thymic health found to predict immunotherapy success in cancer patients

The health of the thymus - a key part of the body's immune system - is associated with cancer patients' outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international study reported at ESMO 2025.

16 Oct 2025

Engineered CAR-NK cells show enhanced cancer killing and immune evasion

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.

8 Oct 2025

Deadly brain cancer erodes skull bone and alters immune marrow

Scientists at Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have shown for the first time that glioblastoma-the deadliest form of brain cancer-affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and interferes with the body's immune response.

3 Oct 2025

Engineered CAR T cells show promise against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers.

2 Oct 2025

Radiomics significantly outperforms clinical models for predicting NPC treatment outcome

Nasopharyngeal carcinoma (NPC) is a highly aggressive malignancy, with most patients presenting at locally advanced stages. While immune checkpoint inhibitors, such as PD-1 blockade, have reshaped treatment strategies, only a minority of patients achieve durable benefit. Accurate biomarkers for predicting treatment response remain an urgent unmet need.

30 Sep 2025

Triple negative breast cancer exploits lymph node niches to block immune defense

In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease.

16 Sep 2025

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

9 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025